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SUMMARY
We introduce the differing methods for culturing healthy
gastric tissue from adult tissues, pluripotent stem cells or
gastric cancer tissue. We also discuss the promise these
systems have for preclinical drug screens and highlight the
applications of organoids for precision medicine.

The stomach is a complex and physiologically necessary
organ, yet large differences in physiology between mouse
and human stomachs have impeded translation of physiological discoveries and drug screens performed using
murine gastric tissues. Gastric cancer (GC) is a global
health threat, with a high mortality rate and limited
treatment options. The heterogeneous nature of GC makes
it poorly suited for current “one size ﬁts all” standard
treatments. In this review, we discuss the rapidly evolving
ﬁeld of gastric organoids, with a focus on studies expanding cultures from primary human tissues and describing
the beneﬁts of mouse organoid models. We introduce the
differing methods for culturing healthy gastric tissue from
adult tissues or pluripotent stem cells, discuss the promise
these systems have for preclinical drug screens, and highlight applications of organoids for precision medicine.
Finally, we discuss the limitations of these models and look
to the future to present potential ways gastric organoids
will advance treatment options for patients with GC. (Cell
Mol Gastroenterol Hepatol 2022;13:19–33; https://doi.org/
10.1016/j.jcmgh.2021.09.005)
Keywords: Stomach; Organoids; Gastric Cancer; Tumor Microenvironment; Preclinical Trial.

T

he mammalian stomach is lined by an ordered
epithelium consisting of invaginated gastric units
housing varied cell types (mucous pit cells, acid-secreting
parietal cells, zymogenic chief cells, and proliferative and
intermediate populations).1 Research into gastric epithelial
biology has long been hindered by lack of accurate models,
as gastric tissue is historically difﬁcult to culture and there
are notable physiological differences between mouse and

human stomachs.2 Recent advances in our ability to culture
3-dimensional (3D) self-renewing organoids from mouse
and human stomachs have opened many possibilities for
studying gastric cells.3–5 In the past decade, researchers
have used gastric organoids to better probe basic stomach
biology, identify cell plasticity, analyze interactions between
the gastric epithelium and immune cells or pathogens such
as Helicobacter pylori, and gain valuable insights into the
progression and treatment of gastric cancer (GC).6–9
GC is a major public health issue, ranking as the ﬁfth most
common malignancy and the fourth-leading cause of cancerrelated deaths worldwide. One study attributed about
770,000 global deaths to GC in 2020 alone.10 Therefore, it is
necessary to improve GC treatments both in terms of efﬁcacy
as well as safety. GC prognosis is poor, with surgery
currently the only curative option.11 However, surgery alone
is oftentimes not enough and multimodal treatments
including incorporation of per-operative chemotherapy is
now routine to increase survival rates.12 For metastatic or
advanced GC, systemic chemotherapy, targeted therapy, and
immunotherapy are the only treatments. Current 2- to 3drug chemotherapy regimens only modestly beneﬁt overall
survival, with median overall survival under 12 months.13,14
Another novel treatment is molecular targeted therapy, but
there are only 2 targeted therapies currently approved and
although many new therapeutics are tested every year, very
few are validated clinically.15
One major hurdle for developing effective treatments for
human cancers is the lack of accurate experimental platforms to identify new therapies and to test efﬁcacy of
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cancer; ORISC, organ-restricted adult stem cell; PD-L1, programmed
death ligand 1; PDO, patient-derived organoid; PDX, patient-derived
tumor xenograft; PSC, pluripotent stem cell.
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therapies on individual patients to personalize their treatment. Animals are useful research models for some aspects
of developing anticancer therapy, such as testing safety and
efﬁcacy of new regimens, yet many drugs that clear preclinical animal trials fail during clinical trials due to differences in animal and human physiology.16,17 As an
alternative, organoids have recently become a popular
in vitro culture model for developmental biology, drug
screening, and disease modeling.18 Organoids can be
developed from human and animal cells and tissues, recapitulate more of the cellular complexity of actual tissues,
and are a common preclinical model.16,17 As well as their
use in the ﬁeld of cancer, gastric organoids have shed light
on stomach development and progressed our knowledge of
pathogenic infection and immune response in the stomach.
Here, we describe the application of gastric organoids to the
study of basic stomach biology and disease states and
elaborate on their potential for implementation in clinical
practice as a guide for precision medicine.

Simulation of these niche signaling cues in an in vitro culture system allows stem cells to proliferate and differentiate
into tissue-speciﬁc cell types. Human gastric organoids are
commonly cultured by seeding gastric glands from human
gastric resection tissue in a basement matrix and culturing
in a medium containing epidermal growth factor (EGF),
R-spondin-1, Noggin, Wnt-3a, ﬁbroblast growth factor 10
(FGF10), gastrin, an inhibitor of ALK5/4/7 (aka TGFBR1,
ACVR1B, or ACVR1C), the small molecule inhibitor A83-01,
and SB202190.27 Using these growth conditions, gastric
glands can grow into gastric organoids.28,29 Alternate
methods exist which rely on co-culturing organoids with
stromal elements rather than extrinsically added growth
factors such as the air-liquid interface (ALI) technique
(Figure 2).30 In the following section, we will describe
technical aspects of gastric organoid modeling and their
derivation from cells that have stem-like characteristics.

Gastric Organoid Culture

ORISC-derived gastric organoids are developed from
primary human stomach tissues. Multiple strategies have
been used to enable long-term growth of stomach tissue
into organoids structures. One protocol uses a collagen type
I gel (Trevigen, Gaithersburg, MD) with an ALI to support
the growth of organoid epithelial structures.31 Organoids
can be grown with fetal calf serum alone, but growth is
improved by supplementation with R-spondin1, similar to
ALI intestinal organoids.30
A second protocol relies on distinct growth factors and
extracellular support provided by laminin-rich Matrigel to
support epithelial growth.32 Notably, Bartfeld et al29 used
this method, based on a protocol developed earlier for culture of mouse antrum,33 to generate gastric organoids from
human antral/pyloric stomach tissue. They isolated gastric
glands from human gastric corpus tissue then seeded them
in Matrigel with media supplemented with various growth
factors (Wnt-3a, R-Spondin-01, Noggin, N2, B27, FGF10,
EGF, gastrin, nicotinamide, etc.). Organoids can be generated
from the gastric cardia and expanded similarly under the
same culture conditions. Matrigel is used to provide a
suitable environment for the embedded gastric glands and
to provide extracellular support. After seeding, human
gastric glands seal and form small cysts that subsequently
expand.

Organoids are stem cell-originated, self-organized 3D
clusters of organ-speciﬁc cells capable of maintaining aspects of the functionality and molecular and cellular heterogeneity of the originating organ. Organoids have been
cultured from many tissues including the brain, retina,
kidney, liver, and intestine.19–23 However, even with the
inherent self-organization capacity of stem cells, elaborate
physiologically relevant tissues cannot be formed in all
conditions. Rather, the experimental environment is paramount in steering cellular development in a highly contextdependent manner.24
Organoids can be derived from 2 sources of stem cells:
organ-restricted adult stem cells (ORISCs) and pluripotent
stem cells (PSCs),24,25 both in the form of induced PSCs and
embryonic stem cells embryonic stem cells (ESCs) (Figure 1,
Table 1). PSC-derived organoids are obtained by mimicking
the sequential signaling interactions operating during
in vivo development, whereas organoids derived from
ORISCs are obtained by replicating signaling cues native to
the respective adult tissues.24 Compared with ORISCs, PSCs
possess a broader potency that allows for directed differentiation into organoids resembling many adult tissues, and
their increased potency also allows for coordinated generation of cells from multiple germ layers. Both fundic and
antral gastric organoids have been developed from PSCs by
the Wells group.4 These PSC-derived organoids do not
require a biopsy and comprise diverse populations of gastric
epithelial cells (like functional parietal and chief cells) and a
surrounding layer of undifferentiated mesenchymal cells.4
On the other hand, ORISCs are epithelial derived, and do
not contain components of the tissue microenvironment,
highlighting their restricted potential compared with PSCs.
Nonetheless, ORISC-based organoids faithfully recapitulate
homeostatic conditions and regenerative processes of the
adult tissue.26
Ultimately, a major application of in vitro organoid cultures is for the study of the in vivo stem cell niche.

Organoids From Organ-Restricted Adult Stem
Cells

Organoids From PSCs
Gastric organoids derived from ORISCs have limitations.
Establishing gastric organoids from ORISCs requires access
to human tissue samples, which is not commonly available
to many laboratories.4 Even when available, the quality of
these tissue samples is widely variable and heavily dependent on timely processing.4 Moreover, ORISC-derived organoids are also further limited for use in cancer studies due
to their lack of microenvironment. An alternate approach is
to generate gastric organoids from human PSCs, which
include both human ESCs and induced PSCs. The unique
ability of PSCs to both self-renew and differentiate into cell
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Figure 1. An overview of
current approaches to
develop gastric organoids in vitro. Gastric organoids can be generated
from 2 sources of stem
cells: ORISCs and PSCs.
ORISCs are mainly derived
from human gastric tissues
samples such as endoscopic biopsy specimens.
Gastric gland cells or
cancerous
cells
were
collected and plated into
the Matrigel matrix. PSCs
include
both
induced
pluripotent
stem
cells
(iPSCs) and ESCs; iPSCs
can be derived from
reprogramed adult somatic
cells or blastocysts. Typically, isolated ORISCs or
PSCs were embedded into
Matrigel matrix domes and
cultured with media supplemented with necessary
growth factors.
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Table1.Characteristics of 2 Different Sources of Organoids
PSC-Derived
Organoids

ORISC-Derived
Organoids

Pluripotency

Yes

Limited

Time needed

6–8 wk

1 wk

High-throughput
screening

Yes

Yes

Modeling human
disease

Yes

Yes

Modeling
organogenesis

Yes

Limited

Precision medicine

Limited

Yes

Feature

ORISC, organ-restricted adult stem cell; PSC, pluripotent
stem cell.

types from multiple lineages permits modeling the whole
organogenesis process in cell culture.24
Recently, Noguchi et al5 used a method to differentiate
mouse ESCs into organoids consisting of gastrointestinal
endoderm surrounded by mesoderm. However, this
approach used mouse ESCs aggregation and spontaneous
differentiation, resulting in heterogeneous organoids.7
Moreover, stomach morphology and regionalization differ
greatly across species,34,35 making animal models like the
mouse stomach suboptimal for simulating the major structure and physiology of the human stomach.7,29,36,37 For
example, the largest volume of the postprandial mouse
stomach is composed of the forestomach, a nonglandular
squamous epithelium similar to the esophagus. The forestomach is not present in humans.29 Thus, to effectively study
human gastric development, physiology, and disease, it is
imperative to use a human model system.
McCracken et al38 identiﬁed a step-wise differentiation
approach to generate human gastric organoids, whereby
PSCs were sequentially differentiated into deﬁnitive endoderm, patterned to posterior foregut, then speciﬁed into a
pure antral epithelium with normal antral cell types. They
began by differentiating PSCs into deﬁnitive endoderm by
adding activin A, a transforming growth factor b family
member that stimulates the highly conserved Nodal
signaling pathway required for endoderm formation across
vertebrate species.39 Endoderm was then patterned into
anterior and foregut endoderm by inhibiting BMP signaling
with Noggin. Foregut spheroids were directed into posterior
foregut by activation of the retinoic acid signaling pathway.
Wnt activation promoted the development of human fundic
gastric organoids, whereas simultaneous MEK inhibition
and activation of the BMP signaling pathway promoted the
differentiation of acid-secreting parietal cells that could be
stimulated by histamine.4,7 These gastric organoids represent the ﬁrst human antrum fully derived in vitro that recapitulates many of the most important aspects of stomach
physiology.38 So far, PSC-derived gastric organoids have
been used as an in vitro system to identify signaling
mechanisms that regulate human stomach development and
physiology, and to model the pathophysiological response of

the
gastric
epithelium
infection.7,38,40,41

to

Helicobacter

pylori

Organoids From Gastric Tumors
To distinguish organoids derived from tumor tissue from
those derived from normal organoids, tumor organoids are
often called tumoroids or patient-derived organoids (PDOs).
A common culture protocol for culturing PDOs follows steps
similar to those used for ORISC-derived organoids.29 In
short, tumor tissue is mechanically disrupted and enzymatically digested, then seeded in Matrigel and supplied
with a certain mixture of growth factors, ﬁnally leading to
PDO formation.29 The ALI method has also been used to
propagate PDOs by embedding the minced tissues inside a
collagen gel with an ALI to support the growth of organoids
epithelial structures.31 Different from normal organoids, the
ALI method allows combined culture of epithelial and
mesenchymal/stromal components like native immune cells
(T, B, natural killer, macrophages) to develop together with
the PDOs,31,42 using a technology already applied to intestinal organoids.43,44 Moreover, unlike normal PDOs, ALIcultured PDOs can grow without A83-01, FGF10, and
Wnt3a.11
One obstacle to obtaining pure PDO cultures is that
patient-derived nonmalignant organoids commonly develop
from healthy cells within the tumor samples.19,45–48 Despite
increased cell division in tumor-derived organoids, the
nontumor organoids can eventually overgrow the tumorderived organoids.45 The reason for this seemingly paradoxical competitive advantage is not clear, but it may be due
to a higher rate of mitotic failure and subsequent cell death
in tumor cells.19 Another factor involved may be that
seemingly normal cells near a tumor may also harbor many
cryptic mutations that confer faster growth than truly
normal tissue from a patient without precancerous or
cancerous lesions.49,50 To circumvent these issues, multiple
strategies have been developed to eliminate contaminating
normal organoids. The ﬁrst approach targets mutational
patterns dictating growth factor dependency of the organoid
culture (Figure 3).45 Many GCs exhibit p53 pathway mutations,51 and this feature can be selected for using the small
molecule Nutlin-3, an MDM2 inhibitor, which stabilizes
TP53 by disrupting the binding of TP53 to its negative
regulator E3 ubiquitin ligase, MDM2.45 Notably, ROCK inhibition plays a signiﬁcant role in the recovery of individualized normal organoid cells. Second, an additional strategy
used has been to culture PDOs in a ROCK inhibitor
(Y-27632)-free medium to enrich for RHO-dysregulated GC
organoids.52 Third, organoids isolated from tumors
harboring EGF receptor signaling pathway mutations can be
selected for by EGF withdrawal or EGF receptor inhibition,
which leads to loss of the patient-derived nonmalignant
organoids.45 Furthermore, if a culture displays a clear mix of
populations, the normal organoids can be simply removed
by phenotype-based manual selection.45 Finally, clonal PDOs
can be established from single cells collected via ﬂowcytometry based cell sorting.45 However, all of these approaches may lessen cellular heterogeneity compared with
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Figure 2. Differences between scaffold-Matrigel and ALI methods to generate gastric organoids. Gastric organoids can
be generated from both scaffold-Matrigel and ALI methods. The scaffold-Matrigel culture system is a common and effective
method to establish gastric organoids. First, isolated cells are mixed with Matrigel, the Matrigel is then allowed to polymerize,
then culture medium supplied with various grow factors is added. For the ALI method, cells are placed onto a hydrophilic
polytetraﬂuoroethylene membrane at the bottom with collagen solution. Different from the scaffold-Matrigel method, the top
layer of the cells is directly exposed to the air instead of submerged in culture media, with only the basal surface keeping
contact with the liquid culture media.

the initial cultures, so it is recommended that early passages
of established cultures be frozen to serve as references for
initial cell content.45
Another consideration for PDO cultures is source tissue
quantity. While surgical resection supplies an abundance of
tissue for initiating organoid cultures, surgery is invasive to
patients and many metastatic or advanced GC patients never
undergo resection. Therefore, esophagogastroduodenoscopy
is ideal for obtaining tissues for organoid creation, especially for advanced patients lacking good treatment options
and for whom testing potential treatments on PDOs is most
beneﬁcial. To address this, Gao et al53 innovated a new
method to develop gastric tumoroids from endoscopic biopsies of patients with gastric adenocarcinoma. They found
that a single endoscopic biopsy of GC can generate organoids that are reﬂective of the overall primary tumor and
may be used for patient-related testing.53 As collection of GC
tissues via endoscopy poses minimal risks to patients, it
may be a plausible way to culture tissue from metastatic or
advanced GC patients who would never undergo resection.

Modeling Disease in Human/Mouse
Organoids
Chronic H. pylori infection is one of the single most
critical factors increasing risk for GC worldwide. Long-term
H. pylori infection in the stomach in many individuals causes
a multistep histopathological cascade known as the Correa
pathway which ultimately leads to GC.54 The use of gastric
organoids has enabled many important discoveries
regarding H. pylori pathogenesis. For example, only a small
percentage of people infected with H. pylori will develop
GC,55 likely owing to genetic factors and/or speciﬁc interactions between host, microbial, and environmental

determinants.56 Strains of H. pylori that produce the virulence factor cytotoxin-associated gene A (CagA) substantially increase stomach cancer risk compared with strains
lacking CagA. Binding of CagA to the ASPP2 (apoptosisstimulating protein of p53-2) causes mislocalization of PAR
members, predisposing the infected cells to lose their cell
polarity and gain an EMT-like phenotype promoted by the
interaction of CagA with Par1b.57 Human gastric organoids
were used to show that a Cherry-tagged CagA-binding
ASPP2 peptide could act as a sponge to reduce the CagAinduced phenotypes, abrogating the loss of cell polarity
and reducing H. pylori colonization.57
Dendritic cells (DCs) in the human gastric mucosa are
thought to be the major antigen-presenting cells that induce
protective immune responses to H. pylori infection.
Recently, Sebrell et al. developed an in vitro co-culture
model by adding human monocyte-derived DCs isolated
from peripheral blood mononuclear cells to organoid cultures.58 They found that bidirectional crosstalk between
gastric mucosal DCs and epithelial cells that were infected
with H. pylori by microinjection contributed to the maintenance of gastric homeostasis and found that DC recruitment
to the gastric epithelium is driven mostly by CXCL1, CCL20,
and possibly CXCL8 following H. pylori infection.58
Another unique ﬁnding from in vitro human studies is
that pathogenic H. pylori infection induces gastric epithelial
cells to express programmed death ligand 1 (PD-L1), an
immune checkpoint ligand known to suppress the immune
system by shutting down T cell effector function.59 Holokai
et al59 found that gastric organoids or monolayers derived
from PSCs or adult tissues could survive chronic inﬂammation by expressing the immunosuppressive ligand PD-L1
throughout the infection and progression to cancer. This
signiﬁes that once a patient progresses to a metaplastic
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Figure 3. Establishing pure GC organoids. As primary tumor tissues often contain nonmalignant cells, nontumor organoids
are commonly seen in patient-derived GC organoid cultures and eventually outgrow the tumor organoids. Therefore, it is
essential to establish pure GC organoids for speciﬁc experiments like drug screening. Removing or adding certain growth
factors in the culture medium allows for establishing pure GC organoids derived from various kinds of lesions such as primary
tumors, metastases, and carcinomatous ascites with noncancerous tissues eventually lost.

state, eradication of H. pylori may not decrease the risk of
developing GC.60 Furthermore, a meta-analysis showed that
PD-L1 expression lasts through GC development, and up to
69% of all GC expresses PD-L1.61
The use of murine gastric organoids has gained popularity in recent years as well. While these murine models do
not fully replicate human stomach physiology or genetics,

mouse models and organoids derived from mouse stomach
mucosa have become a vital tool for studying mechanisms of
tumorigenesis. Mouse gastric organoids are generally
cultured in a Matrigel matrix with growth factors similar to
those described for human culture.33 Dedicated progenitor
cells within adult tissues have been considered the main
candidate cells of origin for cancer,8 yet recent work
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suggests that mature differentiated cells may contribute as
much or more to cancer initiation in the stomach and other
organs, especially in organs without dedicated progenitor
stem cells like the pancreas and liver.62,63 In fact, the idea
that cancers could arise via recruitment of differentiated
cells had been one of the prevailing theories prior to the
dominance of the stem cell theory in the latter half of the
20th century.64 Lineage tracing reporter mice, as well as
tracing of cells that incorporate DNA analogs, have shown
that multiple cells are capable of exhibiting progenitor activity in the stomach in both homeostatic and metaplastic
(ie, precancerous) states. Gastric corpus organoids have
been shown to be able to originate from normal epithelial
progenitors or from proliferating chief cells.65,66 For
example, lineage tracing using a chief cell-speciﬁc marker,
Troy, validated the existence of multipotent progenitor cells
at the gland base in the gastric corpus. Sorted Troyþ chief
cells were able to form long-lived organoids that can
differentiate toward the mucus-producing cell lineages of
the neck and pit region.65 The cellular process by which
mature chief cells re-enter the cell cycle in response to tissue damage was found to be regulated by mTORC1 and
conserved among other cell types from a variety of differing
organs.67 This process has been termed paligenosis.68 Loss
of key genes regulating paligenosis such as Ifrd1/Ddit4 can
result in growth changes in corpus organoids, indicating
that paligenotic chief cells contribute to organoid
outgrowth.69
The ability to genetically manipulate mouse models allows for more speciﬁc studies on disease initiation and
progression. Dysplasia is a key transition state between
precancer and cancer in gastric tumorigenesis.70 Min et al71
derived gastric organoids from a Mist1-Kras(G12D) mouse
model and examined functional roles for Kras activation in
the progression of dysplasia by inhibiting MEK, a downstream mediator of Kras signaling. Kras activation was
found to control cellular dynamics and progression to
dysplasia, and dysplastic stem cells appeared to contribute
to cellular heterogeneity in dysplastic cell lineages.71 Similarly, another group found that KrasG12D expression or p53
loss cause gastric organoids to develop dysplasia and easily
generate adenocarcinoma upon in vivo transplantation.72
Furthermore, TFF1-knockout) mouse–derived gastric organoids readily led to a proinﬂammatory phenotype with a
cascade of gastric lesions that include low-grade dysplasia,
high-grade dysplasia, and adenocarcinomas, indicating that
gastric tumorigenesis may be suppressed by TFF1 impeding
the IL6-STAT3 proinﬂammatory oncogenic signaling axis.73
Mouse organoids have also been well used to better
understand mechanisms of disease development, especially
with regards to H. pylori pathogenesis.74 Morey et al41 used
organoids from both mouse and humans to demonstrate
that H. pylori expression of cgt (the ﬁrst in a series of
H. pylori enzymes) reduced cholesterol levels in infected
gastric epithelial cells, thereby blocking interferon gamma
signaling to allow the bacteria to escape the host inﬂammatory response. The Zavros group has also made extensive
use of mouse organoids as a model to analyze how gastric
tissue responds to H. pylori infections, notably implicating
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the gene CD44 as promoting the increased proliferation
following infection.75 Through these varied uses, mouse
gastric organoids have greatly increased our knowledge of
the gastric epithelial response to injury and disease.

Personalized Medicine for GC Patients
Using PdoS
With the advent of next-generation sequencing, singlecell RNA sequencing, and novel preclinical modeling strategies, GC research is undergoing a radical shift toward
precision medicine.76 PDOs comprise effective tools for genetic evolution studies, biomarker identiﬁcation, drug
screening, and preclinical evaluation of personalized medicine strategies for GC patients. Subsequently, we discuss
how PDOs have contributed to current GC research and
discuss their future possibilities.

Drug Screening
Standard 2-dimensional (2D)–cultured human cell lines
(in other words, standard tissue culture cell lines predominately isolated from malignant cells and cultured on plastic) have been particularly important in drug studies, and
have been the primary source for studying drug responsiveness to identify novel drug targets for decades. Indeed,
results from cell culture studies are a signiﬁcant factor in
deciding whether or not a drug should advance beyond
preclinical trials in humans.77,78 However, the high failure
rate of new drugs that show efﬁcacy and activity in these
traditional preclinical studies has substantially increased
the associated costs of drug development, demonstrating
the need for more representative models of human organ
systems for drug screening during the preclinical phase.78
Moreover, 2D cell lines are prone to genotypic drift and
cross-contamination, may fail to establish permanent cell
lines after long-term culture, and can exhibit loss of tumor
heterogeneity.79 Therefore, organoids (especially from tumors) that lack tumor stroma and vasculature fall in between purely 2D cancer cell lines and patient-derived tumor
xenografts (PDXs) (Table 2).79 Although signiﬁcant medical
advances have been made using standard 2D cell culture
models, these static models cannot effectively recapitulate
the physiology of living tissues.9 In physiological conditions,
cells reside in a complex environment constantly interacting
with other cells and the extracellular matrix; and these interactions are critical for proper tissue differentiation and
function. Organoid culturing techniques promote cell-to-cell
interactions and can oftentimes more precisely mimic
physiological and pathological conditions.80 For example, a
recent study using organoids derived from human breast
cancer showed higher levels of reactive oxygen species
production and increased resistance to cisplatin compared
with standard 2D cell cultures.81 Importantly, organoids
have been shown to exhibit different drug metabolism and
secretion properties due to their different environmental
cues, making them well suited for the study of drug therapies.80 Because organoids more accurately represent human
disease, they have tremendous potential for predicting
in vivo drug sensitivity and responses.82
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Table2.Comparison of Organoids With 2D Cell Lines and PDX Models
Feature

2D Cell Lines

Organoids

PDX

Heterogeneity

-

þ

þþ

Genome editing

þþþ

þþ

-

High-throughput screening

þþþ

þþ

-

Modeling organ development/ disease

þ

þþþ

þþ

Modeling tumor micro-environment

-

þþ

þ

For the representation of each respective feature, þþþ indicates the best, þþ indicates suitable, þ indicates possible,
and - indicates unsuitable.
2D, 2-dimensional; PDX, patient-derived tumor xenograft.

As PDOs retain the heterogeneity and histological characteristics of the primary tumor, they represent an ideal
model for drug screening. Hence, establishing large PDO libraries function as living biobanks and combining with drug
screening might be a powerful tool to delineate novel
therapeutic strategies in GC generally.83 Recently, Yan
et al84 established a primary GC organoids biobank
encompassing normal, dysplastic, and cancerous stomach
tissue as well as lymph node metastases from 34 patients.
This unique GC organoid biobank encompassed nearly all
known GC molecular subtypes and different stages of disease. The authors used this biobank to demonstrate that
large-scale drug sensitivity screening is feasible.84 Their
organoid-based drug screen of 37 anticancer drugs was
timely (taking <2 weeks), and, most importantly, was able
to correlate with actual patient in vivo responses for several
new targeted anticancer drugs including VE822, an ATR
inhibitor.84 These data suggest that organoid based preclinical testing may help guide future cancer therapeutic
choices.
In addition to standard 2D cell cultures, the PDX
model, in which patient cancer cells or tissue are
implanted into immunodeﬁcient mice to recapitulate the
patient’s tumor biology, is also an important preclinical
model.85 However, these PDX models have many inherent
disadvantages including signiﬁcant time and resource
constraints in comparison to PDO models (Table 2). The
organoid drug screening platform will likely be a more
practical route to informing patient treatment and as a
screening tool in clinical trials to accelerate anti-cancer
drug development.84 Moreover, GC organoid biobanks
may serve as a useful tool for drug screening by bridging
the gap between ex vivo and in vivo models by more
accurately portraying the genetic proﬁle of these cancers
while decreasing time and resource costs.83,86 However,
despite the numerous advantages of organoid culture, the
various techniques used to propagate the cultures are still
relatively new and need to be further improved to
enhance drug response and testing.78 Standardizing the
procedures for initiating and propagating gastric tumor
organoids would be beneﬁcial in maintaining biological
relevance and predictability across studies.87 In the next
section, we will discuss the use of PDOs to optimize
personalized cancer treatments.

Precision Medicine
GC is a heterogeneous disease featuring many different
histological and molecular subtypes. Speciﬁcally, GC can be
categorized into 4 major genomic subtypes: microsatellite
instability, Epstein-Barr virus, intestinal (chromosome
instability), and diffuse (genomically stable).51 Each group is
characterized by a distinct molecular proﬁle of genes that
are dysregulated, implicating unique therapeutic targets
within that subgroup of GCs to be further evaluated in
clinical trials. However, despite the pronounced interpatient
and intratumor heterogeneity of GC and our further understanding of the molecular subtypes that make up this
disease, cancer therapy approaches for GC have remained
more or less homogeneous, with uniform treatment strategies used for virtually all patients.
With the advent of novel preclinical modeling strategies
such as in vitro organoid cultures, GC treatment studies are
increasingly focusing on precision medicine.76 The goal of
personalized or precision medicine is to tailor therapy to
speciﬁc patients expressing a certain molecular abnormality
to maximize efﬁcacy and minimize side effects. If PDOs are
going to help us realize the promise of personalize medicine,
it will be critical to ensure that the organoids will mimic the
intratumor and interpatient genetic heterogeneity.88 Updated molecular genetic proﬁling of GC has yielded promising
new therapeutic targets such as receptor tyrosine kinases,
RAS, and PI3K signaling proteins.76 Thus, the integration of
GC genotype, phenotype, and drug sensitivity testing using
PDOs models promises to accelerate the use of personalized
anticancer therapy, to improve treatment outcomes, and to
assist in future clinical trial design and personalized medicine strategies.26,89
Outside classical chemotherapy, only 2 targeted treatments have been approved by the U.S. Food and Drug
Administration to take advantage of genetic alterations as
molecular targets for novel treatment options: the antiHER2 agent trastuzumab and the antiangiogenesis agent
ramucirumab.11,88,90–92 Thus, organoid lines may constitute
innovative molecular subtype–speciﬁc model systems to
test individualized treatment regiments.90 GC organoids
have already been used to help predict patient response to
targeted therapies such as HER2 inhibition.88 Steele et al88
optimized culturing organoids in a 96-well-plate format
for use in drug testing within 3 days of the patient’s surgery,
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making it is feasible to study molecular subtype, perform a
drug screen and provide guidance on individualized adjuvant therapy for each patient within 5–6 days after surgery.
Similarly, Vlachogiannis et al93 cultured cancer-derived
organoids from patients with gastrointestinal metastatic
cancers and treated them with commonly used therapeutics
to predict treatment response. They found 100% sensitivity,
93% speciﬁcity, 88% positive predictive value, and 100%
negative predictive value for organoids forecasting the patient response to targeted agents or chemotherapy.93
Importantly, they were able to mimic interpatient tumor
differences using patient-derived organoids and also
distinguish intra-patient tumor heterogeneity in response to
chemotherapeutic drugs.93 A third study showed that chemoradiation responses in patients were highly matched to
rectal cancer organoid responses, with 84.43% accuracy,
78.01% sensitivity, and 91.97% speciﬁcity.94 These studies
indicate the strength of organoids to predict tumor-speciﬁc
responses and potentially represent a ﬁrst step toward
personalized treatment regimens using PDOs.95
As mentioned previously, Gao et al53 published a novel
technique for establishing GC organoids from endoscopic
biopsies, which may yield clinically relevant results for patients who are ineligible for surgical intervention. Their
technique yielded abundant esophagogastroduodenoscopyderived organoids that could be tested with multiple standards of care drug regimens and combination therapies
within 2 weeks,53 providing a valuable model for predicting
therapies for individual patients with advanced metastatic
GC. PDOs cultured from diagnostic biopsy procedures may
also allow for simultaneous testing of multiple drug regimens to guide therapy in a clinically relevant time interval,
an important step towards personalized medicine for GC
patients.96 As nearly all potential GC patients undergo
endoscopic or diagnostic biopsies during their treatment
course, biopsy-initiated organoids may also allow for
widespread biobanking of not only GC organoids from many
different patients, but also GC organoids from the same
patient during meaningful time intervals throughout their
disease course.96
The promise of in vitro organoid systems for personalized medicine also extends to analyzing or even modulating
the patients’ immune response to disease. Given the advent
of checkpoint inhibitors and immunotherapy in frontline GC
treatment,97–99 better models are needed to study and
optimize these treatments. PDO models are unable to mimic
the in vivo tumor microenvironment completely, as they
normally lack blood vessels for studying cancer angiogenesis
and metastasis, and also lack the immune component found
within the native tumor environment. However, recent
studies have demonstrated that co-cultures of organoids and
immune cells can partially overcome this limitation. The ALI
culture method can preserve the complex histological tumor
microenvironment architecture with tumor parenchyma and
stroma, including functional tumor-inﬁltrating lymphocytes.31 Moreover, this PDO system allows for in vitro
modeling of tumor microenvironment–intrinsic immune cell
responses as opposed to those driven by peripheral
immune populations.31 Dijkstra et al100 demonstrated that
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co-culturing tumor organoids with autologous peripheral
blood lymphocytes can enrich for tumor-reactive T cells
from peripheral blood of patients with mismatch
repair–deﬁcient colorectal cancer and non-small cell lung
cancer. These activated T cells can then kill tumor cells from
the same patient. This provided proof of concept to generate
a novel class of tumor-speciﬁc T cell products derived from
the peripheral blood, and established a means to assess the
sensitivity of tumor cells to T cell-mediated attack in individual patients.100 Moreover, Zavros’ group co-cultured
transgenic mouse–derived gastric tumoroids with autologous immune cells speciﬁcally for the study of PD-L1/PD-1
interactions within the tumor microenvironment.101 Presently, the exploration of organoids co-cultured with immune
cells is still in a relatively early stage, but these ﬁndings are
signiﬁcant and demonstrate that PDOs recapitulate many
key aspects of cancer immunobiology such as upregulation
of checkpoint proteins like PD-L1 that promote immune
evasion and microbial persistence.61,102 These co-culture
models may help optimize the response of effector T cells
speciﬁcally against a patient’s tumor or provide a means to
generate large numbers of effector T cells targeted to tumor
cells for potential adoptive cell transplantation.103 While still
early in development, these GC patient-speciﬁc model systems hold great promise for implementing personalized
medicine and targeted therapy. It is clear that future advances in PDO GC models will allow for combining traditional genome- and phenotype-based strategies to rapidly
advance precision medicine applications.76

Future Perspectives and Limitations
Since the Clevers group discovered the combination of
culture factors needed to maintain the division and differentiation of intestinal stem cells in a 3D environment a
decade ago,3 the worldwide application of organoid technology has resulted in unprecedented advances for many
organs and diseases, including the study of GC.
Owing to the heterogeneous nature of tumors, especially
in GC, no drug can be effective for all patients. Thus,
personalized medicine is needed to advance cancer therapy.
Tumor-derived organoids are rapidly becoming an important tool to realize this goal. Drug screening using human
primary cancer organoids can aid in developing personalized treatment strategies, and PDOs from early-stage human
cancers may even help identify early molecular aberrations
to be used as biomarkers and prevention targets.103 Moreover, organoids can be generated from rounds of biopsies
over time from cancer patients to continuously assess their
treatment response, to detect any developing drug resistance, and to prospectively predict their response to future
therapy options.104 In 2019, Clevers’ group identiﬁed that
tumor organoids can be used to establish individualized
ex vivo model systems to support T cell–based therapies
and to study the interactions between T cells and tumor
cells.100,105 They were able to test for tumor cell sensitivity
and resistance to immunotherapy, potentially allowing for
future unbiased generation of patient-speciﬁc T cell
products.
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Further incorporation and integration of microenvironment components will enable gastric organoids and
tumoroids to more faithfully represent in vivo physiology.
Currently, there are many disparate and evolving techniques
using organoids to study epithelial and niche interactions. A
thorough discussion of this topic is beyond the scope of this
review and is covered in detail elsewhere.101 Speciﬁcally,
microenvironment components may be added individually
to gastrointestinal epithelial organoids such as immune
components.95,101,104 mesenchymal cells,106,107 and even
neurons.108 Developmentally based co-culturing techniques
have also been developed using PSCs that enables differentiation of the mesenchyme together with gastric epithelial
organoids.36 Finally, the ALI technique developed by the
Kuo Lab is an additional 3D gastrointestinal organoid
culturing technique that incorporates multiple components
of the microenvironment including mesenchymal and immune components.29,30,109 Much work is needed to optimize
these co-culturing techniques and to fully elucidate the
limits of this in vitro system.
Techniques for how to best recapitulate the stomach’s
physiology are also rapidly evolving. Human “organs-on-achip,” a multichannel 3D microﬂuidic cell culture chip that
simulates the activities, mechanical properties, and physiological responses of the organ and organ system, is
emerging as a new direction for constructing organoids
models with higher physiological relevance. While organoids rely heavily on spontaneous self-assembly to generate
their organized tissue structure, organoids-on-a-chip provide an artiﬁcial bioengineered system to arrange cells to
simulate tissue or organ physiology.110 In the near future,
additional bioengineering approaches such as live imaging,
genome editing, and single-cell genomics may also be
incorporated into these systems to better study human
organogenesis, diseases and personalized medicine,110
possibly opening new avenues to advance this “next generation” of ex vivo organoid models.
Organoids are robust tools for studying human development and disease. However, it is important to note their
limitations. Drawbacks to gastric organoids in general are
difﬁcult access to the lumen (require microinjection)28 and
the fact that organoids that are passaged over time in vitro
lose the ability to differentiate into functional chief and
parietal cells. Meanwhile, gastric organoid models help
overcome the technical and biological restrictions of in vivo
studies, but they lack nonepithelial cellular components
including mesenchymal tissue, neural cells, and immune
cells, as discussed previously. Another practical limitation
for organoid cultures is the necessity of Matrigel or other
animal-derived matrices in most organoid models to enable
cells to aggregate into organoids.104 The composition of
these matrices is poorly deﬁned, and their efﬁcient removal
is pivotal for subsequent DNA or RNA isolation, CRISPR/
Cas9 editing, or cryopreservation.38,104 In addition, their use
may preclude PDOs from truly being able to be integrated
into CLIA-certiﬁed clinical applications. When studying tumors ex vivo, obtaining pure cancer organoids represents
another crucial hurdle, as tumor organoids can be overgrown and contaminated by normal organoids derived from

healthy gastric epithelial cells intermixed in the starting
tissue material.19,45–47,52 Investigators have begun to
develop sophisticated means to molecularly select for tumor
cells.52,84 While these limitations need to be noted and
accounted for in experimental design, few are insurmountable. In addition, these limitations are also outbalanced by
the many advantages of tumor organoid models such as
their ease of use, beneﬁts of their 3D physiology, and the
ability to test tumor tissue from a patient in a time frame
that allows for clinical decision making. It is clear that
advancing organoid culturing techniques will improve our
understanding of stomach physiology and pathology.

Conclusions
In summary, even though current organoids systems
show limitations and require additional optimization for use
in disease modeling and personalized medicine, they have
opened up important new avenues for regenerative medicine and, in combination with additional bioengineering
approaches, they will continue to be invaluable tools in
preclinical and clinical research.
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